Pfizer Inc (PFE) Stock Price & Analysis
Pfizer Inc (PFE) rose 0.31% to USD 25.7 as of June 9, 2026 at 22:39 UTC, according to Nexqual real-time market data.
PFE last closed at USD 25.62; the session ranged USD 25.47–25.88 on volume of 26,169,316 shares. Market capitalization is $146.48B, with a 52-week range of USD 23.11–28.75 (NYQ). Source: Nexqual, June 9, 2026 at 22:39 UTC.
Key Statistics (as of June 9, 2026 at 22:39 UTC)
| Price | USD 25.7 |
|---|---|
| Change | ▲ 0.31% (up) |
| Previous Close | USD 25.62 |
| Open | USD 25.73 |
| Day Range | USD 25.47 – 25.88 |
| 52-Week Range | USD 23.11 – 28.75 |
| Volume | 26,169,316 shares |
| Market Cap | $146.48B |
| Exchange | NYQ |
Technical Analysis (PFE)
Nexqual's technical model rates PFE "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 22:39 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.82 (neutral) |
| vs SMA50 | Below (USD 26.53) |
| MACD | -0.19 (negative) |
Analyst Ratings (PFE)
Wall Street analysts rate PFE "Buy" based on 27 analysts, with a mean price target of USD 29.19 (range USD 24–36), per Nexqual as of June 9, 2026 at 22:39 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 27 |
| Mean Target | USD 29.19 |
| High Target | USD 36 |
| Low Target | USD 24 |
| Buy / Hold / Sell | 11 / 15 / 3 |
Earnings (PFE)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD 0.68 |
| Revenue Estimate | $14.41B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.75 vs est 0.72 ▲ beat |
| 2025-12-31 | USD 0.66 vs est 0.57 ▲ beat |
| 2025-09-30 | USD 0.87 vs est 0.63 ▲ beat |
| 2025-06-30 | USD 0.78 vs est 0.57 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:39 UTC.
Financials & Fundamentals (PFE)
| Total Revenue | $63.32B |
|---|---|
| Revenue Growth (YoY) | +5.40% |
| Gross Margin | +74.80% |
| Operating Margin | +31.62% |
| Profit Margin | +11.83% |
| ROE | +8.31% |
| Debt / Equity | 71.6 |
| Current Ratio | 1.25 |
| Total Cash | $13.08B |
| Total Debt | $64.73B |
| Free Cash Flow | $12.38B |
Source: Nexqual, June 9, 2026 at 22:39 UTC.
Financial Health Score (PFE)
Nexqual rates Pfizer Inc's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 22:39 UTC.
| Growth | Weak — Revenue -2% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 75%, operating 32% |
| Balance Sheet | Solid — $13.1B cash vs $64.7B debt |
| Cash Flow | Strong — FCF $12.4B, 20% margin |
| Efficiency | Mixed — ROE 8%, ROA 5.7% |
Ownership (PFE)
| Insider Ownership | +0.10% |
|---|---|
| Institutional Ownership | +69.39% |
| Shares Outstanding | 5.70B |
| Float | 5.69B |
| Short % of Float | +2.76% |
Source: Nexqual, June 9, 2026 at 22:39 UTC.
Leadership (PFE)
Pfizer Inc is led by Albert Bourla D.V.M. (age 63), Chairman of the Board & CEO, per Nexqual as of June 9, 2026 at 22:39 UTC.
| Chairman of the Board & CEO | Albert Bourla D.V.M. (age 63) |
|---|---|
| Executive VP & CFO | David M. Denton (age 60) |
| Chief Scientific Officer and President of Research & Development | Chris Boshoff FMedSci (age 61) |
| Senior VP and Chief Scientific Officer of Inflammation & Immunology | Michael S. Vincent |
Major Backers & Investors (PFE)
Notable institutional backers of Pfizer Inc include Fisher Asset Management, LLC, Morgan Stanley, Fidelity, according to Nexqual as of June 9, 2026 at 22:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fisher Asset Management, LLC | 1.84% |
| Morgan Stanley | 1.63% |
| Fidelity | 1.28% |
| Massachusetts Financial Services Co. | 1% |
| State Farm Mutual Automobile Insurance Co | 0.96% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.46% |
| BlackRock | 10.03% |
| State Street | 6.48% |
| Geode Capital | 2.34% |
| Northern Trust | 1.09% |
Source: Nexqual, June 9, 2026 at 22:39 UTC.
From Pfizer Inc's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
- It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
- The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19.
- It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| JNJ | Johnson & Johnson | USD 237 | ▲ 1.82% |
| MRK | Merck & Company, Inc. | USD 119.6 | ▼ 0.99% |
| XOM | Exxon Mobil Corporation | USD 148.91 | ▼ 0.67% |
| VZ | Verizon Communications Inc. | USD 45.78 | ▲ 0.9% |
| JPM | JP Morgan Chase & Co. | USD 312.7 | ▲ 0.11% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:39 UTC. This page is informational and not investment advice.